New PDUFA goal date for ezogabine in the U.S.

New PDUFA goal date for ezogabine in the U.S.

Valeant Pharmaceuticals International (Meda's partner for ezogabine -
known as retigabine outside of the U.S.) has announced that the U.S.
Food and Drug Administration (FDA) has extended the Prescription Drug
User Fee Act (PDUFA) goal date for ezogabine by three months to 30
November 2010. Ezogabine is an investigational anti-epileptic drug being
studied for the adjunctive treatment of adults with partial onset
seizures.

 

 

If questions, please contact: Anders Larnholt, Vice President Corporate
Development & IR ph: +46 709-458 878